quinuclidines has been researched along with Disease Exacerbation in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Criner, G; Dransfield, M; Goodall, EC; Halpin, DM; Han, MK; Ismaila, AS; Lomas, DA; Martin, A; Ndirangu, K; Risebrough, N; Schroeder, M; Shah, D | 1 |
| Clifton, CS; Gross, AS; Hashimoto, K; Ishii, T; Jones, CE; Kato, M; Kilbride, S; Lipson, DA; Nezu, Y; Tomii, K | 1 |
| Hu, J; Jiang, J; Liu, H; Qing, G; Song, X; Su, H; Tu, R; Wang, J; Wang, L; Wang, T | 1 |
| Hanada, S; Kunita, Y; Muraki, M; Sawaguchi, H; Shirahase, K; Tohda, Y; Yamazaki, R | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Htet, A; Moe, S; Ni, H | 1 |
| Crisafulli, E; Torres, A | 1 |
| Asmus, MJ; Boucot, I; Cichoż-Lach, H; Compton, C; Fedele, L; Gabel, K; Grywalska, E; Haggerty, N; Hoddy, KK; Imbert, D; Jarjayes, O; Kowalik, A; Kroeger, CM; Lipson, DA; Michalak, A; Mielnik, M; Molloy, JK; Naya, I; Panda, S; Philouze, C; Ray, R; Roliński, J; Song, J; Thomas, F; Tombs, L; Trepanowski, JF; Varady, KA | 1 |
| Steurer, J | 1 |
| Compton, C; Lipson, DA; Naya, IP; Tombs, L | 1 |
| Baker, T; Briggs, A; Driessen, M; Ismaila, AS; Naya, I; Risebrough, N; Shah, D | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Fahy, WA; Iqbal, A; Maleki-Yazdi, MR; Naya, I; Singh, D; Tombs, L | 1 |
| Appleyard, CB; Chen, Z; Coppola, D; Isidro, AA; Pagán, B; Ren, Y; Wu, J | 1 |
| Christensen, CL; Gerds, TA; Poulsen, HS; Selivanova, G; Willumsen, BM; Zandi, R | 1 |
3 review(s) available for quinuclidines and Disease Exacerbation
| Article | Year |
|---|---|
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
Topics: Anti-Bacterial Agents; Bromides; Disease Progression; Female; Forced Expiratory Volume; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Placebos; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Smoking; Steroids | 2017 |
COPD 2017: A Year in Review.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Common Cold; Disease Progression; Drug Combinations; Eosinophils; Glucocorticoids; Haemophilus Infections; Humans; Interleukin-5; Moraxellaceae Infections; Muscarinic Antagonists; Noninvasive Ventilation; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Seasons; Severity of Illness Index; Tiotropium Bromide | 2018 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
4 trial(s) available for quinuclidines and Disease Exacerbation
| Article | Year |
|---|---|
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Progression; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Health Status; Humans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzoxazines; Cross-Over Studies; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Humans; Japan; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide; Treatment Outcome | 2021 |
Topics: Adult; Age Factors; Aged; B-Lymphocytes; Benzyl Alcohols; Blood Cells; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Disease Progression; Drug Combinations; Female; Flow Cytometry; Forced Expiratory Volume; Humans; Immunophenotyping; Liver Cirrhosis, Biliary; Lymphocyte Activation; Male; Middle Aged; Pruritus; Pulmonary Disease, Chronic Obstructive; Quinuclidines; T-Lymphocytes, Regulatory; Th17 Cells; Treatment Outcome | 2018 |
Topics: Adult; Aged; Benzyl Alcohols; Chlorobenzenes; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Switzerland | 2018 |
8 other study(ies) available for quinuclidines and Disease Exacerbation
| Article | Year |
|---|---|
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Canada; Chlorobenzenes; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Drug Combinations; Drug Costs; Female; Humans; Lung; Male; Models, Economic; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quality-Adjusted Life Years; Quinuclidines; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Datasets as Topic; Disease Progression; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; N-Myc Proto-Oncogene Protein; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Proto-Oncogene Proteins c-myc; Quinolines; Quinuclidines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2021 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β
Topics: Aged; Benzyl Alcohols; Chlorobenzenes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Respiratory System Agents; Secondary Prevention; Symptom Assessment; Treatment Outcome | 2018 |
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Topics: Adrenergic beta-2 Receptor Agonists; Androstadienes; Cost-Benefit Analysis; Delayed-Action Preparations; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Humans; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2018 |
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Benzyl Alcohols; Chlorobenzenes; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Forced Expiratory Volume; Health Status; Humans; Lung; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phenethylamines; Propylamines; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Retrospective Studies; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Transformation, Neoplastic; Colitis; Colonic Neoplasms; Disease Models, Animal; Disease Progression; Immunohistochemistry; Male; Neurokinin-1 Receptor Antagonists; Piperidines; Quinuclidines; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid | 2010 |
PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Genes, p53; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutant Proteins; Quinuclidines; Small Cell Lung Carcinoma; Time Factors; Xenograft Model Antitumor Assays | 2011 |